ANTIBODY-TARGETED IMMUNOTHERAPY FOR TREATMENT OF MALIGNANCY

Despite testing since the mid-1900s, only in the past three years have some monoclonal antibodies provided sufficient efficacy and safety data to support regulatory approval as cancer therapy. Adjuvant-edrecolomab monoclonal antibody was approved in Germany after demonstration of a statistically sig...

Full description

Saved in:
Bibliographic Details
Published in:Annual review of medicine 2001-01, Vol.52 (1), p.125-145
Main Authors: White, Christine A, Weaver, Robin L, Grillo-López, Antonio J
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal, Murine-Derived
Antineoplastic agents
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Combined Modality Therapy
Disease Progression
Humans
ibritumomab tiuxetan
IDEC-Y2B8
Immunotherapy
Immunotherapy - methods
Medical sciences
monoclonal antibody
Neoplasms - immunology
Neoplasms - therapy
non-Hodgkin's lymphoma
Pharmacology. Drug treatments
radioimmunotherapy
Rituximab
Trastuzumab
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite testing since the mid-1900s, only in the past three years have some monoclonal antibodies provided sufficient efficacy and safety data to support regulatory approval as cancer therapy. Adjuvant-edrecolomab monoclonal antibody was approved in Germany after demonstration of a statistically significant 32% improvement over observation alone in the seven-year mortality rate for patients with colorectal cancer. Similarly, trastuzumab monoclonal antibody combined with chemotherapy prolonged the median time to the progression of breast cancer compared to chemotherapy alone. Unconjugated monoclonal antibodies investigated for the treatment of hematologic malignancies include anti-idiotype, CAMPATH-1, and rituximab. Rituximab was the first such therapy approved in the United States for relapsed or refractory low-grade or follicular B-cell non-Hodgkin's lymphoma after demonstration of an overall response rate of 48% and a duration of response of 11.7 months. The radioisotope-conjugated monoclonal antibodies tested as therapy include anti-B1, LYM-1, LL2, anti-CD33, and ibritumomab tiuxetan. Clearly, the full potential of immunotherapy still lies ahead.
ISSN:0066-4219
1545-326X
DOI:10.1146/annurev.med.52.1.125